2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human
PAPER

1421 TP53-independent stress activated protein kinase signaling responses in shwachman-diamond syndrome

Neha Prasad, Noah Saito, BS2, Nozomu Kawashima, MD, PhD3, Kanishk Neerumalla4, Marco Cipolli, MD5, Valentino Bezzerri, PhD6, Seth Corey, MD, MPH7
1 Cleveland Clinic, Cleveland, United States
2 Cleveland Clinic, Cleveland, United States
3 Boston Children's, Boston, United States
4 Cleveland Clinic, Cleveland, United States
5 Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
6 University Link Campus, Rome, Italy
7 Cleveland Clinic, Cleveland, United States

Introduction: Shwachman-Diamond syndrome (SDS) is a rare inherited bone marrow failure syndrome characterized mostly by neutropenia, pancreatic insufficiency, and skeletal abnormalities such as short stature. Approximately 30% of individuals will develop myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). Thus, SDS is considered a leukemia- predisposition syndrome. At least 90% of affected individuals have biallelic mutations in SBDS.  SBDS physically interacts with the GTPase EFL1 to displace the eukaryotic initiation factor (eIF6) from the 60S subunit, facilitating assembly of the 60S subunit with the 40S subunit to form the mature 80S. Loss of SBDS impairs this process, reducing monosome and polysome formation and ribosome recycling. Germline defects in the ribosome are considered key contributors to inherited bone marrow failure syndromes and predisposition to hematologic malignancies. Current dogma states that SDS, like other inherited bone marrow failure syndromes, results from TP53 activation. Somatic biallelic TP53 mutations as a maladaptation drive leukemic transformation in SDS. Our lab has created sbds-/- zebrafish which phenocopy neutropenia, pancreatic atrophy, and decreased length.  Surprisingly, breeding of TP53 loss-of-function mutant zebrafish with sbds-/- zebrafish fails to rescue the neutropenia or lethality. 
Hypothesis: SDS results from TP53-dependent and TP53-independent pathogenic mechanisms. 
Results: To identify these mechanisms, we studied budding yeast, which expresses the SBDS ortholog, SDO1 but lacks TP53 as well as other cell cycle inhibitors such as CDKN1A and CDKN2A. The sdo1Δ mutant yeast exhibited markedly slow growth with a doubling time of ~9 h versus 1.5 h in wild-type. Flow cytometric analysis demonstrated an accumulation in the G2 phase. Yeast are sensitive to environmental stress, including osmotic, oxidative, and heat stress, and show hyperactivation of Hog1, the yeast ortholog of the stress-activated MAP kinase p38, under osmotic stress. Downstream upregulation of the Hog1 downstream target GPD1 occurred. Ptc1is a phosphatase that dephosphorylates/deactivates Hog1 by binding to its activation loop. Overexpression of Ptc1 rescued the growth and cell-cycle defects of the sdo1Δ mutants and suppressed Hog1 activation under osmotic stress. Polysome analysis of sdo1Δ mutants demonstrated ribosome collisions what could explain activation of Hog1. Ribosome profiling (Ribo-Seq) revealed downregulation of metabolic and mitochondrial genes and upregulation of ribosomal genes, confirmed by RT-PCR. This would lead to translational rewiring. In addition, sdo1Δ mutant cells display enhanced activation of the integrated stress response under oxidative stress, including upregulation of the kinase GCN2, phosphorylation of eIF2alpha, and increased expression of the downstream transcription factor GCN4. We observed phosphorylation of p38 in circulating peripheral blood monocytes of individuals with SDS. Moreover, we have shown that p38 inhibitors or shRNA to p38alpha restored growth in HeLa cells that lacked SBDS due to CRISPR/Cas9 editing.
Conclusions:  Our findings demonstrate that ribosome assembly defects in yeast expressing sdo1Δ  and human cells expressing loss of SBDS activate TP53-independent stress pathways, specifically Hog1/p38 providing a novel, druggable mediator of stress signaling in SDS.  Ongoing studies aim to validate our findings in primary human CD34+ hematopoietic progenitor cells with SDS knockdown and patient-derived iPSCs. Ultimately, we wish to show that chemoprevention of p38 activation will reduce the intracellular stress that leads to leukemic transformation.

Neha Prasad: No relevant conflicts of interest to declare.